Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */
×
Free investor livestream — Nov 17

How To Use ChatGPT & Claude To Research Stocks Like A Pro

01
The prompt we use to break down any stock
02
How to fact-check what AI tells you
03
How to compare two stocks in minutes

AstraZeneca says it can power past 2030 without a megamerger

Published Oct 5, 2026
Share:
Summary:
  • CEO Pascal Soriot says AstraZeneca can grow beyond 2030 without a major deal, after chatter about Bristol Myers Squibb.
  • A new Kendall Square hub opens in Cambridge, MA, part of roughly $1 billion invested in the state, with room for 2,000-plus scientists.
  • The stock was little changed Monday and is down 15% year to date.

Why this matters now

Merger rumors with Bristol Myers Squibb knocked the stock earlier, so Pascal Soriot moved to steady expectations. "We absolutely have what we need," he said ahead of the Cambridge, Massachusetts, research hub opening, arguing the company's existing pipeline can drive growth well into the next decade. He did not rule out deals, but said investors sometimes zero in on one or two experimental programs and miss how broad the portfolio is. On Monday, the stock barely budged, and it is down 15% from the beginning of the year.

What is in the pipeline

AstraZeneca is developing medicines in oncology, metabolic disease and rare disorders. Internally, it assumes about a 60% success rate across the full pipeline, down from roughly 75% in recent years when more of the work was in late-stage trials that typically do better. Not every medicine will make it: a recent late-stage breast cancer study failed to beat standard treatment at delaying disease progression.

Whether a drugmaker buys growth or builds it shapes a decade of returns. Market Briefs covers pharma strategy free every weekday.

Boston buildout and the obesity push

The Kendall Square site is the newest piece of roughly $1 billion AstraZeneca is investing in Massachusetts. Over 2,000 researchers will dedicate their efforts to cell therapy, cardiovascular and metabolic disease, and rare disorders. At a ribbon cutting Monday, Soriot said AstraZeneca aims to boost Massachusetts staffing by more than 50% over the coming one to two years. The state recently awarded a $900,000 tax incentive, and Governor Maura Healey told attendees Massachusetts "wants to do everything we can to support you and keep you here doing the incredible and life-changing work that you are doing."

AstraZeneca's obesity efforts are increasingly anchored in Boston. Over roughly two years, the company has assembled a local team to lead development of its weight loss portfolio, including oral options and next-generation approaches that could move dosing to monthly rather than weekly injections. The plan is to stand out by addressing excess weight alongside related metabolic risks such as high cholesterol, hypertension and diabetes, with medicines that may ultimately unite weight reduction with therapies for those issues in one pill. "What we have that nobody has is this ability to combine and treat patients who have risk factors," Soriot said.

The bigger shift to the U.S. and the talent race

Soriot said innovation in the U.S. has pulled ahead of Europe, one reason AstraZeneca is leaning more into America. For years, the company emphasized R&D and put comparatively limited capital into manufacturing, so it now needs new facilities to support medicines coming out of its labs. He said policies under President Donald Trump accelerated the industry's move toward U.S. manufacturing, though AstraZeneca would have needed more capacity regardless. He framed the fight for pharmaceutical leadership as increasingly a U.S. versus China contest rather than a race with Europe or Japan.

You can see the competition in Boston. A growing group of biopharma companies - particularly obesity players - are intensifying hiring and broadening the available talent. Zealand Pharma A/S of Denmark launched a new Cambridge location last week.

MassBio says industry jobs in Massachusetts doubled from 2013 to nearly 117,000 in 2023, but last year marked the first decline in headcount in decades as the industry cooled and rivalry increased from other U.S. states and overseas markets, notably China. AstraZeneca's new labs are meant to help it attract those workers.

What this means for your money

AstraZeneca is betting on its own pipeline and a bigger U.S. footprint rather than chasing a blockbuster merger. The story to watch is straightforward: clinical readouts, how fast Kendall Square fills up, and whether new manufacturing keeps pace. Keep an eye on the obesity portfolio and later-stage studies. If they hit, Soriot's confidence about the post 2030 runway could look a lot more like execution than optimism.

Saying no to a mega-deal is itself a bet on the pipeline. Join Market Briefs free and watch how it pays off.

Disclosure

Recent News

1 2 3 … 133

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

November 20, 2026
Anthropic Stock at $1.5 Trillion: Why This IPO Isn't Amazon in 1997

Anthropic has gone public at a valuation of about $1.5 trillion, while Amazon went public in 1997 at around $440 million. Anthropic has about $33 billion in revenue this year and no profit, and investors are paying more than 40 times its sales, against about 3 times for Amazon. Briefs Finance CEO Jaspreet Singh says nobody knows what comes next, and that long-term investors use downturns to buy instead of panic selling.

Read More
November 17, 2026
Is the Stock Market Going to Crash? Why Nvidia and the Fed Have Investors on Edge
  • Tech stocks are selling off because investors don't know who will lead Nvidia, the company that has been funding the AI industry and selling it chips.
  • Inflation has the Federal Reserve planning to raise interest rates, with a hike expected in December, and that puts pressure on homebuyers, private equity and the $40 trillion national debt.
  • Briefs Finance CEO Jaspreet Singh says nobody has a crystal ball, so his rules are to buy when markets are low, hold long term and invest only what you're willing to lose.
Read More
November 16, 2026
The $40 Trillion National Debt: Trump's 4-Part Plan to Make It Feel Smaller
  • The national debt is above $40 trillion, and the Federal Reserve has gone from sending Washington its profits to losing money.
  • President Trump's four-part plan leans on shorter-term debt, stablecoin companies buying Treasuries, a bigger balance sheet and government stakes in private companies.
  • The goal is to outgrow the debt, not pay it off, so Jaspreet Singh points investors to the seven industries where Washington wants growth.
Read More
November 16, 2026
The Fed Is Talking About a Jumbo Interest Rate Hike. It Has No Easy Way Out
  • The Fed makes its next rate decision on December 9 and is now talking about jumbo interest rate hikes of 0.5%, though one in December looks unlikely.
  • Washington will pay a record $1.05 trillion in interest this year on $40 trillion of debt, and that debt resets at higher rates as the Fed hikes.
  • Jaspreet Singh's five moves are to pay down variable-rate debt, earn interest on your savings, know which stocks feel the pressure, look at value and hedge.
Read More
November 16, 2026
Buying on Margin Is at a Record High. Here's the Risk for the Stock Market
  • Margin debt, the money investors borrow to buy stocks, is at a record of around 4.6% of GDP, up from 3.9% in 2021.
  • ETF money has more than tripled in five years to 7% of GDP, while corporate buybacks and 401(k) money sit below their earlier peaks.
  • Margin calls and panic selling can make the next downturn deeper, so Jaspreet Singh keeps buying broad market funds and says most investors should skip margin debt.
Read More
November 16, 2026
Housing Prices Are Falling. Buying a House Still Isn't Cheaper
  • Housing prices have fallen for four straight weeks, but mortgage rates around 7.2% keep the monthly payment about where it was in 2023.
  • Talk of a jumbo Fed rate hike and a plan to sell Fannie Mae and Freddie Mac on the stock market could both push mortgage rates higher.
  • Briefs Finance CEO Jaspreet Singh treats a house as a liability: buy within your budget and let your investments build the wealth.
Read More
November 14, 2026
Nvidia News: Jensen Huang Is Out, and the "Bank" Behind American AI Just Lost Its Founder
  • Jensen Huang is out at Nvidia over affairs with multiple people, and the company he founded has been the bank of American AI, with about $30 billion into OpenAI and $10 billion into Anthropic.
  • A hotter-than-expected inflation report has Fed officials talking about a possible 0.5% hike in December, and gold, silver, and bitcoin fell on the news.
  • President Trump said the US may not need a deal with Iran, keeping oil prices and inflation risk high. Jaspreet Singh breaks down what it all means for AI stocks and your portfolio.
Read More
November 14, 2026
Record Highs, a 57-Year Low in Jobless Claims, and a Stock Market Bubble: Inside the Weirdest Market in History
  • Stocks are booming at the fastest pace in years, jobless claims just hit a 57-year low, and most investors still feel like nobody is hiring.
  • The Fed is protecting the dollar over the economy, oil swings on every Iran headline, and a few AI companies are carrying an S&P 500 where four of five stocks sit in a correction.
  • Jaspreet Singh explains why circular financing between Nvidia, OpenAI, Anthropic, and SpaceX rhymes with 2008's house of cards, and how his three investing pillars handle a stock market bubble.
Read More
November 14, 2026
Is a Recession Coming? The Fed Just Made a U-Turn It Has Only Made Twice in 60 Years
  • The Fed has raised rates, cut them, then raised them again only twice in the last 60 years, and both times the economy fell into a recession and stocks crashed.
  • The same stop-and-go cycle is playing out now, with one big difference: US debt is 125% of GDP today versus about 30% in 1980.
  • In the 1970s gold rose roughly 24x, real estate 157%, stocks lagged, and cash lost half its value. Jaspreet Singh lays out five assets to consider before the next flip.
Read More
November 14, 2026
The 2027 Tax Brackets Are Out: How Some Investors Can Earn $135,300 and Pay $0
  • The IRS 2027 tax plan keeps the same seven rates but widens every bracket and lifts the married-filing-jointly standard deduction to $33,200.
  • The 0% long-term capital gains bracket rises to $102,100, so a household living on $135,300 of investment income could owe $0 in federal income tax.
  • C corporations still pay 21%, small businesses keep the 20% QBI deduction, and the 401(k) limit climbs to $25,500 with an $8,500 catch-up for investors over 50.
Read More
1 2 3 … 33
Share via
Copy link